 LAVAL, QC and CAMBRIDGE, England, May 28, 2021 PRNewswire - Liminal BioSciences Inc. Nasdaq: LMNL Liminal BioSciences or the Company, a clinical-stage biopharmaceutical company, announced today that based on interim pharmacokinetic PK results from the ongoing fezagepras multiple ascending dose MAD study, the Company has decided to stop its plans to move fezagepras into a Phase II clinical study in Idiopathic Pulmonary Fibrosis and a phase IaIIb study in Hypertriglyceridemia, as it evaluates the impact of the PK data profile observed in the on-going study. The Company is continuing to evaluate the interim PK results. 